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Abstract
Huntington’s disease (HD) is a heritable, neurodegenerative disorder characterized by
motor, cognitive, and psychiatric disturbances. An unstable CAG expansion within the gene
normally encoding for the Huntingtin protein is responsible. The expanded mutant form of
Huntingtin and the putative protein co-factor Rhes interact and cause cell death within the
striatum. We hypothesized chronic treatment with simvastatin, a cholesterol lowering drug,
would disrupt the biosynthetical pathway which gives both Rhes and its target cells binding sites
and render Rhes inactive. Healthy and HD mice were treated with simvastatin or a vehicle.
Animals’ motor behavior was assessed with three separate tests over the first four months of life.
No significant differences were found between the HD groups; however, the HD treated animals’
performance on the rotarod test, at month 4, was intermediate between healthy mice and HD
vehicle treated mice. The results hint at simvastatin’s therapeutic potential, but are interpreted
cautiously.

Huntington's disease; Rhes; statin; mevalonate; Huntingtin protein; rotarod
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Introduction
Huntington's Disease (HD) is a debilitating neurodegenerative condition with no cure or
treatment that can delay or prevent the onset of symptoms. It is a progressive, dominantly
inherited disorder that interferes with the motor, cognitive, and psychiatric functioning of
afflicted individuals. The disease stems from a single mutation on the short arm of human
chromosome 4. The C (Cytosine) A (Adenosine) G (Guanine) trinucleotide repeat in this region
encodes for a poly-glutamine stretch of the protein huntingtin (Htt) and, under normal
conditions, may have up to 34 repeats. An extension beyond 37 glutamines is unstable and
results in a mutated form of huntingtin (mHtt), ensuring HD. The mHtt protein undergoes
changes in makeup and shape, causing the formation of intracellular protein aggregates.
Presently, researchers are fervently attempting to uncover the either destructive or protective
nature of such aggregates. While mHtt has emergent toxic capabilities, it simultaneously
prevents the function of Htt, which aids activity, and survival of the neurons that are susceptible
in HD (Cattaneo, Zuccato, and Tartari, 2005). Although huntingtin is expressed ubiquitously
throughout the body, the hallmark of HD neuropathology is severe loss of neuronal cells only in
the striatum and, to a lesser extent, the cortex (Reiner et al., 1988), suggesting that there is a
permissive cofactor within cells of these regions. The subcortical striatum is a portion of the
basal ganglia, a set of structures responsible for behavioral activation (Kandel, Schwartz, &
Jessell, 2000.) In humans, the striatum is comprised of the caudate nucleus and putamen. These
structures receive input from the cortex, the thalamus, and the substantia nigra pars compacta.
Striatal output eventually reaches the cortex via connections in the thalamus, substantia nigra
pars reticulata, and the globus pallidus. Within the striatum, GABAergic medium spiny neurons
are particularly vulnerable, experiencing up to a 95% loss in advanced stages of HD (Graveland,
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Williams, & DiFiglia, 1985; Albin, Reiner, Anderson, Dure, Handelin, Balfour et al., 1992). The
striatum is also home to the preferentially expressed protein Rhes (Ras homologue enriched in
the striatum). The exact mechanisms of HD neuronal degeneration is unknown, but many have
implicated the intracellular inclusion bodies exhibited in affected neurons and some have named
the intriguing Rhes as a possible cofactor. These are just two possible targets for developing
therapeutic strategies.
George Huntington’s original description of the disease offers a glimpse into what life is
like for those carrying the HD mutation (1872). He detailed a familial condition entailing
involuntary, choreic movements, behavioral and psychiatric disturbances, and an ultimate
dementia state. Although dance-like motor perturbations were noted and remain the hallmark
feature, giving HD it’s original namesake of Huntington’s chorea, the complex and pervasive
nature of the disease is now fully appreciated. With a lifetime prevalence rate of 1 in 10,000 for
those of European descent, symptoms begin to emerge in middle adulthood, between ages 30 and
50, for the majority and gradually progress for the next 10-15 years until death (Craufurd,
Thompson, & Snowden, 2001). The process is extremely distressing and even painful. As
Huntington initially accounted, suicide is often an accompanying feature of the illness. Indeed,
there is evidence of increased suicide rates among HD patients, particularly for those in the early
stages of the disease (Schoenfeld, Myers, Cupples, Berkman, Sax & Clark, 1984). Studies on the
sequence of symptom onset have yielded inconsistent findings, although many agree that some
compilation of psychiatric, behavioral, and cognitive changes frequently present before motor
disturbances (de Boo, Tibben, Hermans, Jennekens-Schinkel, Maat-Kievit, Roos, 1999;
Lawrence, Hodges, Rosser, Kershaw, ffrench-Constant, Rubinsztein et al., 1998; Roos, 2010). A
survey of the literature has found largely varied estimates of lifetime prevalence rate among HD
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patients for psychiatric symptoms, between 33% and 76%, based on varying assessment
methodologies (van Duijn, Kingma & van der Mast, 2007). Such symptoms are often considered
to be the most troubling facet of HD, over motor symptoms, and are an important point of
consideration when caregivers and patients are deciding on hospitalization options (Hamilton,
Salmon, Corey-Bloom, et al., 2003). Three clusters of psychiatric features, each with its own
longitudinal trajectory, have emerged in the research: apathy, irritability, and depression. Apathy
tends to continually progress over time and through all stages of the disease. Irritability increases
throughout the disease, but more so in early stages. Lastly, depression, the most common
psychiatric symptom, is a point of contention. Many hold that depression is most common in the
middle stages of the disease, while others point out increased rates even in pre-clinical samples
(Julien, Thompson, Yardumian, Snowden, Turner & Craufurd, 2007; Paulsen, Nehl, Hoth, Kanz,
Benjamin, Conybeare et al., 2005). Demonstrated declines in depression have been attributed to
anti-depressant medication relief (Thompson, Harris, Sollom, Stopford, Howard, Snowden &
Craufurd, 2012). Psychiatric conditions may deteriorate so greatly in later stages of the disease
that psychosis emerges. In 5%-16% of HD patients, a psychosis similar to that of schizophrenia
occurs, complete with paranoid delusions and auditory hallucinations (Tsuang, Almqvist, Lipe,
Strgar, DiGiacomo, Hoff et al., 2000)
Early cognitive changes are regularly cited by clinicians and family members (Kirkwood,
Siemers, Hodes, Conneally, Christian & Foroud, 2000). Neuropsychological testing has shown
early deficits in visuo-spatial skills, affective processing, concentration and executive
functioning. It has been argued that the pattern of cognitive weaknesses is distinct from other
basal ganglia disorders and cortical dementias (Lawrence, Sahakian, Hodges, Rosser, Lange &
Robbins, 1996). Specific affected abilities include, but are not limited to, pattern recognition,
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spatial working memory, information processing speed and capacity, planning, problem solving,
concept formation and decision making. As time goes on, memory deficits come to the forefront
of clinical presentation. Short-term and long-term memory show decline, in memory acquisition,
delayed recall, and with contention, recognition (Zakzanis, 1998). Brain imaging analyses have
revealed that progression of subtle cognitive deficits to more severe impairments results from the
progression of deterioration from striatal to extra-striatal tissue, namely the insular lobe, to the
frontal and temporal cortex. Specifically, the connectivity in the fronto-striatal circuit is thought
to be the driving force behind HD cognitive deficits (Montoya, Price, Menear & Lepage, 2006;
Peinemann, Schuller, Puhl, Jahn, Weindl & Kassubek, 2005).
Striatal degeneration is directly responsible for the prototypical symptom of HD, chorea,
as well as many other motor features. Chorea is defined as unwanted, involuntary movements of
extremities that can be described as dance-like. Beginning in distal extremities, like fingers and
toes, as well as small facial muscles, these twitches develop from mild to moderate classification
(Roos, 2010). Other early, even pre-clinical indications are abnormal saccadic eye movements,
brisk muscle stretches, and decreased ability to quickly alternate movements (Penney et al.,
1990). Slower reaction times have also been cited, but like other early indicators of imminent
disease, the literature is inconsistent on this point (de Boo, Tibben, Hermans, Maat, & Roos,
1998)de Boo, Tibben, Lanser, Jennekens-Schinkel, Hermans, Maat-Kievit & Roos, 1997;
Kirkwood, Siemers, Bond, Conneally, Christian & Foroud, 2000). Although accounts of early
and pre-manifest motor symptoms are continually revised, all of the above are accepted as
eventual symptoms. In addition, akinesia, or problems with initiating movement, bradykinesia,
slowness in performing movement, and dystonia, abnormal and contorted posture are prominent
features (Rosas, Salat, Lee, Zaleta, Pappu, Fischl et al., 2008).
4

Huntingtin
Htt is an elusive protein, of which the structure and function are not completely
understood. Unlike other proteins with a high molecular weight (~348 kDa), it is completely
soluble and is expressed throughout the human and rodent body, both in and out of the nervous
system (Cattaneo, Zuccato, and Tartari, 2005). The highest concentrations are found in the
central nervous system and the testes (Gil & Rego, 2008). It is made up of 3,144 amino acids, of
which only a few motifs have been identified. Htt is known to consist of the poly-glutamine
section which holds the HD mutation, an adjacent region rich in the glutamate derived, nonessential amino acid proline, and 4 clusters of HEAT repeats (named for the first 4 proteins they
were found in: Htt, Elongation factor 3, the A subunit of protein phosphatase 2A, and TOR1),
sequences of ~40 amino acids that are duplicated at various points along the protein structure
(Andrade, Petosa, O’Donoghue, Muller, & Bork, 2001; Li & Li, 2004).
The function of Htt has only recently begun to be understood. Its wide distribution
throughout the cell has complicated the search for function. It is localized to both nuclear and
cytoplasmic structures, such as the endoplasmic reticulum, the Golgi apparatus, synaptic
vesicles, and mitochondria (DiFiglia, Sapp, Chase, Schwarz, Meloni, Young et al., 1995;
Hilditch-Maguire, Trettel, Passani, Auerbach, Persichetti, & MacDonald, 2000; Kegel, Meloni,
Yi, Kim, Doyle, Cuiffo et al., 2002; Li, Plomann, & Brundin, 2003). Information on the structure
and interacting proteins of Htt has helped elucidate its function. The poly-glutamine tract begins
at the 18th amino acid position and, when in normal or wild-type-type form, elongates to no more
than 34 repeats (Huntington’s Disease Collaborative Research Group, 1996). Earlier studies
suggested that the multiple glutamines formed a “polar zipper” facilitating binding between Htt
and transcription factors which also contained a poly-glutamine stretch (Perutz et al., 1994). In
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fact, Htt interacts with multiple partners (Harjes & Wanker, 2003; Zuccato, Valenza, & Cattaneo,
2010). The poly-proline rich portion of the protein is thought to be necessary for the formation of
inclusion bodies, perhaps by affecting solubility (Steffan et al., 2004). HEAT repeats are present
in many other large eukaryotic proteins involved in transport processes in the nucleus and the
cytoplasm as well as chromosome separation, indicating this may be also true of Htt (Neuwald &
Hirano, 2000).
Further evidence for the role of Htt in transporting processes stems from its Carboxylterminal nuclear export signal (NES) and a less active, non-conventional nuclear localization
signal. Their presence allows for the movement of Htt to and from the nucleus, likely as part of a
larger nuclear-cytoplasmic shuttling complex. In mHtt, the NES is cleaved away, leaving the
protein able to enter the nucleus, but not exit (Xia, Lee, Taylor, Vandelft, & Truant, 2003).
In addition to development and transport processes such as protein and vesicle
trafficking, Htt is thought to be involved in cytoskeletar anchoring, postsynaptic signaling,
transcriptional regulation, and serves an anti-apoptotic role intracellularly (Caviston & Holzbaur,
2009; Gil & Rego, 2008; Kegel, Meloni, Yi, Kim, Doyle, Cuiffo et al., 2002; (Rigamonti et al.,
2000). HD neurodegeneration is now known to be a result of both a loss of the diverse wild-typetype Htt functioning and a toxic gain of functioning of mHtt (Landles & Bates, 2004). The many
proposed mechanisms leading to the devastating degeneration are all rooted in the decreased
expression of functional Htt and the increased expression of pathological mHtt.
mHtt Aggregation
Early investigations of HD neuropathology in mice and humans described the presence of
intra- and extra-nuclear inclusion bodies within neurons of all cortical layers and medium sized
striatal neurons (Davies, Turmaine, Cozens, DiFiglia, Sharp, Ross et al., 1997; DiFiglia, Sapp,
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Chase, Davies, Bates, Vonsattel & Aronin, 1997). These aggregates differ in composition, with
nuclear bodies consisting of NH-terminal mHtt fragments and extra-nuclear bodies consisting of
both fragments and full length mHtt (Cooper, Schilling, Peters, Herring, Sharp, Kaminsky, et al.,
1998; Martindale, Hackam, Wieczorak, Ellerby, Wellington, McCutcheon, et al., 1998). Their
presence is due to the expanded polyglutamine portion of mHtt, which induces a conformational
change that is thought of as the starting point for downstream pathogenesis. Normally, exon 1 of
Htt, made up of 17 polyglutamine residues, has an N-terminal α helical structure. The shape is
flexible and transforms into a well-defined α helix, a random coil, or a loosely-bound and
extended loop conformation at various, randomly determined points along the glutamine chain.
This flexibility creates a low threshold for interference from outside influences, such as length of
polyglutamine tract and neighboring protein motifs (Kim, Chelliah, Kim, Otwinowski,
Bezprozvanny, 2009). Not surprisingly, mHtt’s first exon, which contains upward of 17 residues,
has its conformational flexibility taken advantage of. In this case, the random coil portion of the
polyglutamine expansion misfolds into a hairpin structure, described as two anti-parallel β
strands and a sharp turn (de Mezer, Wojciechowska, Napierala, Sobczak, & Krzyzosiak, 2011).
Aggregates are thought to be formed by separate, but likely simultaneous, pathways. The
first involves proteolysis, the process by which proteins are degraded either partially into
peptides, or completely into their amino acids. Specifically, NH-terminal mHtt is cleaved by two
classes of enzymes, caspases (notably caspase-3 and caspase-6) and calpains, which leave behind
mHtt fragments that have a propensity for diffusing into the nucleus and aggregating (Gafni &
Ellerby, 2002; Goldberg, Nicholson, Raper, Kalchman, Koide, Graham, et al., 1996; Graham,
Deng, Slow, Haigh, Bissada, Lu, et al., 2006; Sun, Fan, Balciunas, Cooper, Bitan, Steavenson et
al., 2002; Wellington, Ellerby, Hackam, Margolis, Trifiro, Singaraja, et al., 1998). These
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fragments recruit further proteases, thereby creating a positive feedback loop which results in
amplified aggregation until ultimately, some propose, the cell dies (Gil & Rego, 2008). Secondly,
aggregation is dependent upon protein misfolding which Htt normally protects against (Fink,
1999). In the absence of mHtt, chaperones, Heat-shock protein 70 (Hsp70) and heat-shock
protein 40 (Hsp40), coordinate to correct misfoldings and maintain the solubility of Htt (Hartl &
Hayer-Hartl, 2002). If misfoldings remain after these chaperones are active, the ubiquitinproteasome system (UPS) degrades the target proteins (Voges, Zwickl, & Baumeister, 1999).
However, if the misfolded protein, in this case mHtt, is being generated faster than the
chaperone-UPS buffer can act, aggregation will begin, only to be further exacerbated by the
sequestering of precious chaperones and proteasomes within the aggregates themselves (Hay,
Sathasivam, Tobaben, Stahl, Marber, Mestril et al., 2004; Martin-Aparicio, Yamamoto,
Hernandez, Hen, Avila, Lucas, 2001). While mHtt’s misfolding contributes to aggregation, Htt
inhibits the activity of certain fragment inducing caspases and interacts with corrective
chaperones, demonstrating that such aggregation is the result of both a gain and loss of function.
An ongoing controversy exists over the role of mHtt aggregates in HD
neurodegeneration. Earlier research labeled mHtt aggregates as cytotoxic. This argument centers
around the presence of intracellular aggregates in several neurodegenerative diseases and the
correlation between aggregation and cell death (Yang, Dunlap, Andrews, & Wetzel, 2002).
Indeed, aggregates do seize important classes of proteins that also contain a poly-glutamine tract
and facilitate or regulate transcription, as well as parts of the essential proteasome mentioned
above (Cha, 2007). Overexpression of such proteasome components reduces aggregation and
prolongs cell life (Carmichael, Chatellier, Woolfson, Milstein, Fersht & Rubinsztein, 2000,
Vacher, Garcia-Oroz, Rubinsztein, 2005). Others contend that aggregation is a noncausal,
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incidental phenomenon of cellular dysfunction (Kuemmerle, Gutekunst, Klein, Li, Li, Beal et al.,
1999). Evidence for a more “side-effect” role is found in studies of human post-mortem HD
brains that demonstrate the highest number of aggregates in the cortex, rather than the most
severely affected area, the striatum (Gutekunst, Li, Yi, Mulroy, Kuemmerle, Jones, et al., 1999).
It has also been shown that neuropil aggregates of the dendrites and dendritic spines are much
more common in HD brains than the seemingly more detrimental nuclear aggregates, and that
peripheral nervous system tissue displays a number of mHtt inclusion bodies (Moffitt, McPhail,
Woodman, Hobbs, & Bates, 2009). Furthermore, a mouse model containing a particular fragment
of the full length HD gene indicates it is not the aggregates themselves that are driving neuronal
loss. The model displays early and widespread neuronal nuclear inclusions, but no signs of
neuronal dysfunction or death (Slow, Graham, Osmand, Devon, Lu et al., 2005).
Still a third argument is made for a neuroprotective capacity of aggregates. Aggregation
sequesters mHtt and decreases the amount of diffuse or soluble form of mHtt in other cell
locations. Alterations in the length, and thus aggregation, of mHtt have shown related decreases
in the number of neuronal aggregates and death (Ratovitski et al, 2009). Moreover, survival
analysis has shown that inclusions actually predict cell survival, indicating the presence of
aggregation could be a coping mechanism of the cell (Arrasate et al., 2004). Interestingly, the
same sequestration by mHtt aggregates affects mammalian target of rapamycin (mTOR)
(Ravikumar et al., 2004). This kinase is a negative regulator of autophagy, the process by which
cells clear mHtt and alleviates toxicity and behavioral symptoms in HD (Jia, Hart, & Levine,
2007).
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Rhes
In the midst of still a largely unknown function of Htt and mHtt’s aggregates, clues can
be found in an emerging line of research devoted to a possible co-factor in HD pathology, the
protein Rhes. As evident by its name, Rhes or the Ras homolog enriched in the striatum, is
selectively located in areas most vulnerable to HD degeneration. It is an intermediate sized
guanine-nucleotide binding protein (Falk, Vargiu, Foye, Usui, Perez, Danielson et al., 1999).
Similar to prototypical Ras proteins, Rhes has GTP binding and effector domains and a CAAX
box (composed of a Cysteine which attaches to membranes, two aliphatic amino Acids, and one
of several amino acids, X). It also has an extended C terminal which adds to its molecular weight
(Harrison, 2012). The function of Rhes remains unclear but it is involved in dopamine-mediated
signaling and behavior (Harrison & LaHoste, 2006; Spano, Branchi, Rosica, Pirro, Riccio,
Mithbaokar et al., 2004). Rhes mRNA in the striatum was decreased by depleting the striatal
dopamine input.
Research from Johns Hopkins University’s group has substantially added to the literature
on Rhes and HD. In vitro studies demonstrated that Rhes binds to both Htt and mHtt, but holds
preference for mHtt. Notably, Rhes does not bind to ataxin, another protein containing a polyglutamine repeat that is charged with neurodegeneration in spinocerebellar ataxia, indicating a
role specific to HD pathology. The most influential finding from their work, however, was that
the overexpression of Rhes in cells containing mHtt decreased cell survival by 50%. This
decrease was not found when either Rhes or mHtt was overexpressed singly, nor was it shown in
cells expressing both Rhes and Htt. Depletion of Rhes using RNA interference increased rates of
cell survival. Likewise, they found that, in mHtt knock-in striatal cells, overexpression of Rhes
further decreased cell survival by 60% overall. There were no toxic effects found when
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overexpression was conducted in Htt knock-in cells (Subramaniam, Sixt, Barrow & Snyder,
2009).
The researchers subsequently demonstrated that Rhes augments neuronal death by
influencing sumoylation. Sumoylation is a post-translational modification process in which a
small ubiquitin-like modifier is covalently attached to various proteins and a change in
functioning results. When mHtt undergoes sumoylation, aggregation is reduced and
neurotoxicity is increased (lending support to the notion that non aggregated, soluble mHtt is
toxic) (Steffan, Agrawal, Pallos, Rockabrand, Trotman, Slepko et al., 2004). Rhes enhances
sumoylation of mHtt, but not Htt, in a time and concentration dependent manner; thus, the
potential cofactor is responsible for the disaggregation of mHtt bodies and consequential
cytotoxicity (Subramaniam, Sixt, Barrow & Snyder, 2009). Work from our laboratory
(Baiamonte, 2012) corroborates a cytotoxic Rhes scenario. Novel in vivo work demonstrates that
HD mice without the Rhes gene are less susceptible to the motor deficits and neuropathological
markers of HD.
Mevalonate Pathway
The mevalonate pathway is one of the most studied biological synthesis pathways in the
human body. The pathway is named for the 3-hydroxy-3-methylglutaryl- CoA (HMG-CoA)
derivative, mevalonate. It is the foundation for the production of essential compounds such as
dolichols, ubiquinones and, most notably, cholesterol. These structures and their products serve
several key functions like steroid and hormone production, synthesis of glycoproteins, cell
respiration, and lastly, maintaining membrane integrity (Fritz, 2009). Furthermore, the pathway
produces two isoprenoids, or prenyl groups: farnesylpyrophosphate and
geranylgeranylpyrophosphate. Both are implicated in post-translational modifications of small
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GTP-binding proteins, like those in the Ras super family (Takai, Sasaki & Matozaki, 2001). Such
proteins are pivotal in intracellular signaling, cell growth and differentiation, and gene
expression (Goldstein & Brown, 1990; Hinson, Chambliss, Toth, Tanaka & Gibson, 1997).
Following the pattern of Ras proteins, Rhes shares a chemical structure that involves
prenylation (Hancock, Magee, Childs & Marshall, 1989; Vargiu, De Abajo, Garcia-Ranea,
Valencia, Santisteban, Crespo et al., 2004). Prenylation, or isoprenylation, is the process by
which a prenyl group, farnesylpyrophosphate (FPP) or geranylgeranylpyrophosphate (GGPP), is
added to the C-terminal cysteine(s) of peptides and proteins by farnesyltransferase or
geranylgeranyltransferase, respectively. The hydrophobic prenyl groups serve several purposes.
They may act as anchors, tying together the target protein and a cell membrane or two separate
proteins. In fact, the majority of prenylated proteins are localized to cell membranes. After
prenylation, Ras proteins undergo proteolysis and then C-terminal methylation, which is
stimulated by GTP binding in membranes (Backlund, Simonds & Spiegel, 1990; Zhang & Casey,
1996). Proteolysis and methylation facilitate proper membrane association, but the initial
prenylation is essential.
Given that the mevalonate pathway and its numerous metabolites influence such a large
and diverse group of proteins, much interest lies in the therapeutic potential of mevalonate
interference. Two main classes of interfering pharmaceuticals exist: those that inhibit CAAX box
post-translational modification and those that inhibit the pathway’s key enzyme, HMG-CoA
reductase. The first group interferes with the intermediate processes. Farnesyltransferase
inhibitors (FTIs), geranylgeranyltransferase inhibitors (GGTIs), and dual prenyltransferase
inhibitors (DPTIs) prevent the prenylation of proteins. By preventing the transfer of farnesyl,
geranygeranyl groups, or both, to CAAX box motifs, these drugs also prevent the localization of
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affected proteins to cell membranes and thereby interfere with signal transduction. Since small
GTP proteins, like H-, K-, and N-Ras, are the most common culprits of oncogenic mutations,
there has been an impressive exploration of oncogenic therapies utilizing FTIs, GGTIs, and
DPTIs (Gao, Liao & Yang, 2009). In vitro and in vivo studies have exhibited antitumor effects of
FTIs and GGTIs. FTIs have been successful in directly inhibiting tumor development in a
majority of cancer cell lines (Sepp-Lorenzino, Ma, Rands, Kohl, Gibbs, et al., 1995). Similarly,
animal models have shown that FTI driven inhibition of Ras prenylation is a valid means of
therapy in colon, pancreatic, lung, prostate, bladder, and breast cancer (Ayral-Kaloustian &
Salaski, 2002).
Acting at the beginning point of the pathway are HMG-CoA reductase inhibitors, or
statins. HMG-CoA reductase serves as the pathway’s rate limiting enzyme, transforming HMGCoA into mevalonate (Kuzuyama & Seto, 2012). Lipid lowering statins are widely used to treat
hypercholesterolemia, reducing the likelihood of heart attacks and stroke. Statins have also been
explored in AD models, and recently, have been named as a possible treatment for HD
symptoms. Alzheimer’s research has generated several notable findings. Epidemiological studies
have shown that chronic statin use was associated with decreased risk for AD (Jick, Zornberg,
Jick, Seshadri & Drachman, 2000). In vitro experiments showed that statins reduce amyloid beta
protein production, which composes the hallmark plaques of AD pathology (Simons, Keller, De
Strooper, Beyreuther, Dotti & Simons, 1998). In corroboration, statins drive decreases in
amyloid beta peptides in vivo (Fassbender, Simons, Bergmann, Stroick, Lutjohann, Keller, et al.,
2001). Statins could also have therapeutic effects based on their regulation of isoprenoids.
Mevalonate derived compounds, FPP and GGPP, but not cholesterol, are dramatically elevated
in human AD brains. In vivo treatment with Simvastatin, a highly effective statin, significantly
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reduced both isoprenoids in mice (Eckert, Hooff, Strandjord, Igbavboa, Volmer, Muller &
Wood, 2009). Clinical trials using statins have shown mixed results, though the cholesterol
pathway hypothesis of AD remains prominent (Hoglund & Blennow, 2007; Shepardson, Shankar
& Dennis, 2011).
Because HD and AD are both neurodegenerative diseases involving intranuclear
inclusion bodies and possible Ras contribution, HD research is following suit and beginning to
explore what the mevalonate pathway contributes to disease. In an inducible mHtt model,
increased expression of mHtt in striatal cells reduced the transcription of several genes involved
in the mevalonate pathway, notably the gene encoding for HMG-CoA reductase (Sipione,
Rigamonti, Valenza, Zuccato, Conti, Pritchard, et al., 2002). Similar expression effects have been
found in the brains of HD humans and mice that have an overexpression of exon 1 fragment of
the mHtt gene (Mangiarini, Sathasivam, Seller, Cozens, Harper, Hetherington et al., 1996).
Valenza and colleagues also found that altered cholesterol biosynthesis results in lower overall
cholesterol mass in cultured mHtt cells, cortical and striatal tissue of HD mice (2005).
Importantly, by adding exogenous cholesterol into striatal mHtt neurons, they were able to rescue
the cells in a dose dependent manner.
In contrast, Del Toro and colleagues (2010) argue that augmented cholesterol
homeostasis in HD takes the form of cholesterol accumulation and altered cellular distribution
which contributes to excitotoxicity. Because accumulation has been documented in striatal
neurons and tissue of full length mHtt mice, researchers aimed to visualize and quantify lipid
distribution within striatal mHtt cells (Trushina, Singh, Dyer, Cao, Shah, Parton, et al., 2006).
Compared to cultured Htt cells, mHtt cells showed a 24% increase in cholesterol, distributed in
the plasma membrane and intracellular deposits. Similarly, in vivo striatal neurons of full length
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mHtt mice exhibited a 25.7% increase in total cholesterol. Not surprisingly cultured striatal cells
and neurons that contained mHtt also demonstrated an increase in cholesterol-rich, highly
ordered portions of the plasma membrane and those in the cytosol. Healthy Htt cells have only
sporadic places of highly ordered domains, with more fluid membranes in the cytosol. Because
NMDA receptors are located within such high cholesterol areas, known as lipid rafts, the extent
of membrane order influences how susceptible neurons are to NMDA mediated excitotoxicity.
Administration of simvastatin caused decreases in plasma membrane order, reduced lipid rafts,
and protected against NMDA excitotoxicity in both Htt and mHtt cells. Interestingly, simvastatin
treatment did not reduce overall cholesterol levels, supporting earlier work which suggested
simvastatin redistributes plasma cholesterol content in other brain areas without increasing total
levels (Burns, Igbavboa, Wang, Wood & Duff, 2006; Paolisso, Sgambato, De, Gambardella,
Verza, Varricchio, & D’Onofrio, 1991; Thelen, Rentsch, Gutteck, Heverin, Olin, Andersson, et
al., 2006).
In addition to altering membrane configuration, the statins’ early point of interception in
the mevalonate pathway allows the drugs to block downstream protein prenylation. Statins
prevent the synthesis of isoprenoids farnesylpyrophosphate and geranylgeranylpyrophosphate,
which as described above, are necessary for the anchoring prenylated proteins to membranes or
other proteins (Jasinska, Owczarek & Orsulatk-Michalak, 2007). Whereas FTIs, GGTIs, and
DPTIs inactivate the enzymes that achieve prenylation, statins eliminate the prenyl groups
themselves. When normally prenylated proteins do not have the machinery to attach to
membranes, their following signaling processes are prohibited. Rhes, like all Ras superfamily
members, are among such prenylated proteins. In fact, non-pharmacological disruption of Rhes
farnesylation prevented its sumoylation and subsequent disaggregation of mHtt, as well as Rhes-
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mediated cytotoxicity (Subramaniam, Sixt, Barrow & Snyder, 2009). Statins offer a clinically
relevant means to inhibition of Ras prenylation, an important step toward unlocking a treatment
for not just AD, but HD as well.
In summary, statins hold promising potential for HD pathology on two fronts. First,
statins’ cholesterol lowering effects could attenuate cholesterol accumulations found in striatal
neurons of HD patients and mice. A decrease in such accumulations is protective against
NMDA-mediated excitotoxicity, one proposed mechanism of HD degeneration. More relevant to
the presently proposed research, statins may pharmacologically interfere with the putative
cofactor, Rhes. By compromising plasma membrane integrity and blocking prenyl group
synthesis, statins can prevent the prenylation of Rhes, thus, rendering the striatally expressed
protein inactive.
Purpose and Hypothesis
Current evidence implicates the soluble form of striatal mHtt and the protein Rhes, which
adds to soluble levels, in HD degeneration. The majority of this work, with the exception of
recent findings from our laboratory (Baiamonte, 2012), has been conducted in vitro. Therefore,
in vivo exploration of Rhes’ role in HD remains essential. The current study aimed to inactivate
Rhes, and thus mHtt, via de-prenylation and/or removal of membrane localization using a
clinically relevant mode, a commercially available and extensively researched statin, simvastatin.
By administering chronic statin treatment, established Rhes prenylation and membrane
localization was proposed to be eliminated and further prenylation to be prevented. Such an
effect would hypothetically be manifested as decreased HD motor deficits. It was hypothesized
that HD mice receiving the drug treatment would show significantly better performance on
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measures of motor ability and motor related markers of neuropathology than HD mice receiving
no treatment.
Methods
Animals
Breeding. All animals used in the study were derived from cross-breeding the wild-type
genotype of a Rhes knockout line obtained from Dr. Daniela Spano (Spano, Branchi, Rosica,
Pirro, Riccio, Mithbaokar et al., 2004) with R6/1 transgenic mice bearing the human mutated
Huntington’s allele (115 CAG repeats). The current breeding colony is maintained from an
original HD R6/1 cohort purchased from The Jackson Laboratory (Bar Harbor, ME). All animals
used were homozygous for the native Rhes allele, and either carried (hemizygous HD) or did not
carry (NC) the mHtt gene. Of the 13 HD animals, 5 were placed in the drug treatment group,
while 8 were used as controls. Of the 11 NC animals, 4 were treated with the drug and 7 were
used as controls.
Material and Apparatus
Rotarod Apparatus. The rotarod device (Med Associates, Inc., Georgia, VT) is designed
to assess animal motor coordination and balance. It is made of a suspended, rotating horizontal
bar attached on both sides to the center of a 38 cm-wide metal wall. The walls, and thus, the bar,
rotate at a rate of 16 revolutions per minute (rpm). The bar is 30 mm in diameter and positioned
27 cm above a floor of soft bedding material. The height of the bar is intended to encourage the
animal to continue walking as to avoid a fall, but in the event of falling the bedding acts as a
protective padding.
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Suspended Bar. The suspended bar task is also used to measure motor coordination and
balance. The set up consists of a wooden pole 1 cm in diameter positioned 30 cm. above a
protective floor of animal bedding.
Triple Beam Balance. Animals’ body weights were measured using an OHAUS® triple
beam balance. Animals were placed in an attached, covered metal container which allows for
proper measurement.
Analytical Balance. A Mettler Toledo AG64 scale was used to calculate all food and drug
administration. The scale has the capacity to measure masses within 1 mg. It is further equipped
with a glass shield which protects against drafts, minimizing environmentally caused fluctuations
in reading.
Transgenic mouse dough. A soft dough diet, designed for transgenic mice (Bioserv,
Frenchtown, NJ) was used as animal diet. The dough allows for even incorporation of drugs and,
thereby, accurate dosing. The dough has been successfully used to deliver mevalonate interfering
drugs (Capell, Olive, Erdos, Cao, Faddah, Tavarez et al., 2008).
Simvastatin treatment. Simvastatin (Zocor® Merck & Co., Inc. Whitehouse Station, NJ)
was generously provided by Dr. Lee Roy Morgan.
Procedure
Genotyping.
Tissue collection and digestion. Tissue used for genotyping was collected from animal
tail snips. Mice were anesthetized prior to tail biopsies using an intraperitoneal injection of
ketamine/xylazine solution (100/8 mg/kg). Pinches to the tail and foot which elicit no reflex
ensured proper depth of anesthetization. After deemed anesthetized, a sterile straight razor blade
removed the end 2-3 mm of tail tissue. Wounds were cauterized and antibiotic ointment was
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applied. The harvested tissue was immediately placed in a solution of 300µl of DirectPCR™
(Viagen Biotech Inc., Los Angeles, CA) lysis reagent and 11.5µl of proteinase K. Samples were
incubated at 55˚C overnight while cell lysis occurs and then at 85° for one hour to deactivate the
proteinase K. After tissue digestion is completed, purified DNA samples are stored at 4˚C
indefinitely.
Polymerase Chain Reaction (PCR). To determine Rhes genotype, primers (Invitrogen,
Grand Island, NY) for Rhes wild-type and Rhes EGFP, which recognizes only the null mutation
of Rhes, were utilized. Primers for the mHtt allele were used to detect HD carrier animals. For
PCR of the Rhes WT allele, 0.5 µl of DNA and 3 µl of both the sense and antisense primers were
added to a solution containing 12.5µl GoTaq Green MasterMix ™ (400 µM dNTPs, 3mM
MgCl2, Taq Polymerase, and reaction buffer), and 12.5 µl of nuclease free H2O. To amplify the
HD gene, the same measurements of PCR ingredients were used, except for an increased amount
of DNA, 2 µl, and a reduction of nuclease free H2O from 12.5 µl to 9.5 µl.
Gel Electrophoresis. Ten µl of each PCR product were loaded into a 3% agarose gel. A
100 bp ladder was used in each gel to aid in the estimation of allele length. Gels were input with
35v of power for 5 minutes to ensure DNA migration out of each well and then with 95v until
visible PCR products reached the edge of the gel. Afterwards, gels were stained with 0.5 µg/ml
solution of ethidium bromide. Stained gels were placed on a Biorad™ UV lightbox in a darkened
room which allows for visualization of DNA markers.
Drug Administration.
Due to the longitudinal design of the current study, statin treatment was delivered in the
animals’ food. Simvastatin was chosen over several other available statins based on its higher
potency, greater capacity to cross the blood brain barrier, and more widespread use clinically
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(Saheki, Terasaki, Tamai & Tsuji, 1994; Shepardson, Shankar, & Selkoe, 2011). Pills were
crushed using a pestle and mortar, and then sifted to filter out the pill coating. Drug doses were
measured and dyed using food coloring. Dyed drug was then mixed into mouse dough by hand.
The dye enabled the preparer to thoroughly and evenly blend the drug and food mixture in
proportions that take into account body weight and food consumption. Animals were treated with
a clinically relevant dose of 80 mg/kg of body weight daily for 3 months, beginning on post-natal
day 30. The literature shows simvastatin effects in daily doses ranging from .125 mg/kg to
100mg/kg (Aprahamian, Bonegio, Rizzo, Perlman, Lefer, Rifkin & Walsh, 2006, Zhang, Mao,
Luo, Wei, Berggren-Soderlund, Nilsson-Ehle & Xu, 2011). HD and NC mice were fed transgenic
mouse dough either unmodified or containing simvastatin according to random assignment.
Motor Assessment.
Rotarod Performance. Using the rotarod apparatus at a fixed speed of 16 rpm, motor
coordination and balance was measured once every 30 days over a 4 month period. Latency to
fall was recorded over three 60 second trials for each animal, with a 60 second rest period
between each trial. If an animal remained on the rod after 60 seconds, it was removed and the
time was recorded as 60 seconds. Based on established protocol and considering habituation
effects shown in unpublished data of our laboratory, each animal underwent one day of
habituation prior to the first day of behavioral testing and then a 60 second habituation trial prior
to first testing trial. The best score over three trials was used for each animal in analyses.
Suspended Bar Performance. After all rotarod assessments were completed for a test day,
animals underwent suspended bar testing. Animals were placed on the edge of a 30 cm high
wooden dowel facing an open space. Latency to turn 180 degrees or to fall off was recorded.
Inconsistent findings exist on how healthy mice behave in such a situation, but the original report
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holds that animals will attempt to turn away from the dangerous edge. HD mice are known to
lose their balance while managing the dowel (Mangiarini, Sathasivam, Seller, Cozens, Harper,
Hetherington et al., 1996). Like the rotarod task, animals were habituated on the day prior to the
start of testing. However, no 60 second practice trials were given on the first test day. The
scoring of 3 trials were collapsed for a maximum daily score of 180 seconds.
Clasping Behavior. After each animal completed the suspended bar task, their limb
movements during midair, ground-facing suspension were assessed. Healthy wild-type animals
normally splay their limbs outward, while HD animals tend to clasp their front and back limbs
inward (Mangiarini, Sathasivam, Seller, Cozens, Harper, Hetherington et al., 1996; Rubinsztein,
2002). Every animal was assessed during a 10 second trial, with 10 second rest periods in
between. For each limb that was pulled in toward the body, the animal received a score of 1.
Thus, every trial offered an opportunity to gain a maximum score of 4, while every testing day
may have resulted in a score of 12. Animals were habituated on the day prior to their first day of
testing.
Body Weight Assessment.
On each test day, animals’ body weights were measured following the suspended bar task.
Differences between HD and wild-type type animals in weight gain and overall weight have been
demonstrated. HD mice have been shown to stop gaining weight when their symptoms begin and
progressively lose weight as the disease advances (Mangiarini, Sathasivam, Seller, Cozens,
Harper, Hetherington et al., 1996). Furthermore, the novel dough has a higher fat concentration
than typical mouse diets contain, necessitating the assessment of weight gain and loss and
comparison to previous research.
Results
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The data were first examined for statistical outliers. Due to small sample sizes, extreme
values were left unchanged, with one exception. A single NC control animal performed two
standard deviations below the mean at month 4, a critical time point for detecting treatment
effect, and was removed from all analyses. Analyses were performed using SPSS for Windows
(version 19.0) with the probability of a Type I error set at 0.05. Data for each dependent variable
was analyzed in two ways. First, a 2 x 2 x 4 mixed design Analysis of Variance (ANOVA) was
conducted and then a two-factor, 4 x 4 mixed design ANOVA. The first analysis contained two
between-subjects factors, treatment group assignment and HD carrier status. In the latter
analysis, there was one between-subject factor, group assignment (4 levels consisting of HD vs
NC animals in either a treatment or control group) and one within-groups factor, age at testing
(1-4 months). Separate mixed ANOVAs were performed on rotarod, suspended bar, clasping,
and body weight data. Significant F-ratios were followed by Tukey’s post hoc tests to control for
family wise error. Significant interactions of group and age at testing were subjected to tests of
simple effects.
Analysis of Rotarod Performance
Rotarod performance data are summarized in Figure 1. Each animal’s best performance,
measured as the longest latency to fall from the rod, from three test trials was used. Analysis
with a 2 x 2 x 4 ANOVA yielded a non-significant three-way interaction of treatment group, HD
carrier status and testing age [Greenhouse-Geisser F (1.05, 21.05) = 1.29, p = .271]. Using a 4 x
4 design, a significant two-way interaction of group, including both treatment and HD carrier
status groups, and testing age occurred [F (3.16, 21.05) = 3.40, p = .035], indicating that the
groups differed in how their respective performance changed across the 4 months. Mauchly’s test
of sphericity indicated the data violated the assumption of equal variances among group
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differences. The Greenhouse-Geisser F ratio was interpreted to correct for this violation. The
conservative Tukey’s HSD post-hoc tests subsequently revealed that although NC animals
performed better than HD animals, and HD animals treated with the drug outperformed nontreated HD animals, the group mean differences were not significant when analyzed across all
time points. However, a follow up one-way ANOVA of rotarod performance at only month 4,
revealed significant group differences [F (3, 23) = 3.19, p = .046]. Post-hoc tests confirmed
group differences in performance. The mean difference between the worst performing group
consisting of HD untreated animals (M = 41.18, SD = 18.32) and the better performing groups
made up of NC treated (M = 58.46, SD = 4.08, p = .063) and untreated animals approached
significance (M = 60, SD = 0, p = .095). The HD animals treated with simvastatin (M = 51.58,
SD = 12.68) performed at an intermediate level between NC groups and HD untreated animals
(Figure 2). Lastly, comparison of group differences shows that HD treatment group was not
significantly different from the HD control group.

Figure 1
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Rotarod performance across ages 1-4 months
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Figure 2
Rotarod performance at age 4 months
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HD Veh

Analysis of Suspended Bar Performance
Neither a 2 x 2 x 4 ANOVA [Greenhouse-Geisser F (1.77, 36.88) = 2.51, p = .101]; nor
the 4 x 4 design [Greenhouse-Geisser F (1.74, 34.87) = 2.44, p = .108] calculated for suspended
bar performance showed a significant main effect of testing age. Analyses of interactions were
also conducted and indicated no significant differences among groups in performance across all
4 months using a 2 x 2 x 4 design [F (1.77, 36.88) = .85, p = .42] or a 4 x 4 design [F (5.23,
34.87) = .46, p = .81]. Without significant interactions, post-hoc tests were not conducted.
Analysis of Clasping Behavior
Clasping data are summarized in Figure 3. The 2 x 2 x 4 ANOVA failed to show a
significant three-way interaction between treatment group, HD status, and testing age [F (3, 63)
= 2.54, p = .064]. Using a 4 x 4 design, a significant two-way interaction [F (9, 60) = 5.44, p <
.0001] was observed between group and testing age variables, indicating that some groups
experienced an increase in clasping behavior over time, while others did not. Post hoc analysis of
month 4 data, using a one-way ANOVA, indicated that, as expected, untreated HD animals (M =
7.25, SD = 6.04) showed significantly, or at a trend level, more clasping behavior than NC
animals, both untreated (M = 0, SD = 0, p = .052) and treated (M = 0, SD = 0, p = .018). Similar
to the rotarod data, treated HD mice (M = 6.4, SD = 5.18) displayed clasping levels that were
between NC animals and the HD untreated group. However, the differences between HD treated
mice and all other groups were not significant and the variability in all animals displaying
clasping behavior was quite high.
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Figure 3
Clasping behavior across ages 1--4 months
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Analysis of Body Weight
The 2 x 2 x 4 ANOVA showed no interaction between treatment group, HD status, and
testing age [Greenhouse-Geisser
Geisser F (1.85, 37.03) = .98, p = .381]. The 4 x 4 ANOVA yielded a
significant testing age x group interaction [F (5.56, 37.03) = 3.59, p = .008]. The GreenhouseGeisser correction was again employed due to a violation of sphericity. Across all time points, no
group’s mean performance significantly differed from another, as assessed by Tukey’s HSD.
Examining only differences in weight at month 4, by means of a one
one-way
way ANOVA, no groups
were found to differ significantly.
Discussion
Consistent with the current study’s hypothesis, findings indicate that chronic simvastatin
treatment was related to decreased motor deficits in animals carrying the HD gene, as measured
by the rotarod task. The effects of the drug simvastatin, are visible at the animals’ fourth month
1

of life. Whereas untreated HD mice showed significant motor impairment compared to treated
NC mice, the motor performance of simvastatin-treated HD mice was not significantly different
from controls. However, their performance fell between that of NC mice and untreated HD
mice, being not significantly different from any other group, including untreated HD mice. While
the HD control mice performed worse than both NC groups at the statistical trend level, the HD
treated mice were considerably closer in performance to NC mice. Importantly, the data are
consistent with recent findings from our laboratory, which show that depletion of the Rhes
protein, by means of genetic manipulation, causes decreased HD-related motor deficits and, thus,
better performance in the rotarod task, beginning at the 4 month age (Baiamonte, 2012). The
effects of Rhes depletion remained at the fifth and sixth month tests. HD/Rhes depleted animals,
which are analogous to the current study’s HD treated animals, did ultimately show motor
impairment compared to NC animals, though not until the age of five months.
Similar to what was found in the Rhes depletion study, the current study failed to yield
any significant effects of age or group in suspended bar performance. Although the suspended
bar task was created to measure motor coordination, it is likely that the task did not capture such
an ability, as even NC mice did not consistently display the measured behavior, turning in the
opposite direction from a heightened ledge. Through observations, it was apparent that the mice,
in fact, demonstrated more exploratory behaviors than evasive behaviors. It is possible that the
mice became desensitized to the height of the ledge. Researchers have thought a heightened
ledge produces an anxiety-like state in the mice, resulting in an attempt to flee the situation
(Baiamonte, 2012). However, if no dangerous consequences are encountered initially without the
mice successfully turning a full 180 degrees, continued anxiety when placed on the ledge and
resulting turning behavior are unlikely. By even the first day of testing, all mice had received 3
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trials of habituation, allowing reasonably sufficient time for animals to either learn a non-turning
evasive technique, such as back pedaling a few centimeters from the ledge and then stabilizing
oneself, or to become desensitized to the ledge in general.
Despite rotarod data that indicated decreased motor deficits in treated HD mice, clasping
behavior, which is an indication of neurodegeneration, was not affected overall. At month 4,
there was no difference between the treatment and control groups of HD animals. Both HD
groups showed a tendency to pull their limbs inward toward their stomach, as opposed to
splaying their limbs outward as the NC animals did, when suspended upside down in the air.
Interestingly, the treated HD mice showed a decrease in clasping behavior from month 3 to
month 4. These findings suggest that simvastatin may affect motor areas of the brain
differentially. Although behaviors necessary to both the clasping and rotarod tasks are governed
by the striatum and its neural projections, simvastatin could potentially influence Rhes neurons
in some encapsulated striatal areas while not affecting others. HD is a progressive
neurodegenerative disorder, and clinical findings hold that the progression’s speed and specific
course vary across individuals (Roos, 2010). HD patients show different patterns of symptom
onset across their lifespan. Following this argument, even the HD mice studied here, which all
have equal CAG repeat length known to influence progression, display varied deficits. For
example, 3 animals of the HD control group failed to show any clasping behavior in the 4
months they were tested. Surely these animals will begin to show clasping behaviors at later time
points as they lose more and more brain mass.
The current study found a lack of significant weight loss usually exhibited by HD animals
when their symptoms begin. Neither treated nor untreated HD mice weighed significantly less
than NC mice at any time point. The diet given to all animals in the study is likely responsible.
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The soft dough has a higher fat content (14%) than regular hard pellet food commonly fed to
experimental rodents (roughly 4%). Notably, the mice did not have unusually heavy weights and
did not display any negative side effects of the food.
Taken together, the behavioral data point toward a drug effect limited in its capability to
attend to HD motor deficits and neurodegeneration. Previous research has shown that Rhes acts
as a potential cofactor, along with mHtt, to cause HD neurotoxicity. It is argued that Rhes binds
to mHtt and enhances sumoylation, the post-translational modification which increases that
amount of toxic soluble mHtt (Subramaniam, Sixt, Barrow & Snyder, 2009). Simvastatin, in this
study, could possibly be attenuating HD motor deficits by preventing Rhes to attach to its normal
membrane location prior to mHtt binding. The drug blocks the mevalonate pathway which
generates the compounds used by Rhes to anchor to cell membranes. Simvastatin treatment
could, in contrast, be acting via membrane alteration. By decreasing the lipid concentration of
membranes, the drug treatment used here may be lowering the number of NMDA receptors and,
in turn, decreasing NMDA-mediated excitotoxicity (Trushina, Singh, Dyer, Cao, Shah, Parton, et
al., 2006). Given the contradictory results of drug treatment in the rotarod and clasping task, two
measures shown to be influenced by Rhes protein levels, it is possible that simvastatin is not
influencing Rhes activity at all.
Though the data are promising, they should be interpreted with caution, as the study has
several shortcomings. First, the sample sizes were quite small, with unequal group numbers. In
addition, no examination of simvastatin in brain tissue was conducted. While there is no reason
to suspect that simvastatin, which holds a high potency, absorption rate, and ability to cross the
blood-brain barrier, would not be reaching the target brain areas, such a confirmation is
necessary.
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There are many questions generated from this experiment. Future studies are needed to
confirm the drug effect, gather details about its activity, and explore the potentially therapeutic
use in clinical populations. To address this study’s limitations, the drug’s presence in the brain
needs to be confirmed. By comparing neural sections following gross neuroanatomical markers,
researchers can gain valuable information on simvastatin’s penetration into separate areas with
markedly different behavioral roles. In order to confidently conclude the drug effects these data
suggest, a physiologically appropriate concentration of simvastatin needs to be demonstrated in
the striatum. Examination is underway which will use homogenized brain tissue of various areas
and employ thin layer chromatography, nuclear magnetic resonance spectroscopy, and high
performance liquid chromatography to quantify drug concentrations.
Due to the patterns in behavioral measures which showed separation between HD and
NC animals only beginning at month 4, the current animals will continue to be assessed at 5 and
6 months of life. As HD control mice continue to show declines, any protective drug effects will
only become more apparent. There is considerable room to decline, as some HD control mice
had not begun to show HD motor deficits or clasping behavior even at month 4. In light of the
small sample sizes used, a continuation of drug effects requires HD treated animals to perform
significantly better than HD control animals. The most supporting evidence for simvastatin’s
benefits would be generated if the HD treatment group maintained comparable behaviors to NC
groups on the rotarod task. The exact mechanisms of action are also yet to be understood.
Simvastatin could be influencing the putative co-factor Rhes, altering cell membrane integrity in
general, or both. Further studies utilizing cell culture and Rhes protein visualization and
localization are warranted.
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Furthermore, exploration in a human clinical population may prove less straightforward.
Although epidemiological studies propose links between statin use and decreased risk for
neurodegenerative diseases (Jick, Zornberg, Jick, Seshadri & Drachman, 2000), little work has
been done toward clinical trials of statins for relief in those that have such diseases. It should be
noted that before such work can be conducted, more information is needed on statins’ effects on
the cognitive and psychiatric symptoms accompanying diseases like HD.
In conclusion, these findings hold promise for the development of pharmacologic
therapies in HD. The novel treatment produced interesting differences in motor behavior within a
small sample, despite variability in symptom severity. If subsequent testing at later ages produces
similar results, simvastatin would be the first drug utilized to alleviate the motor symptoms of
HD. This drug holds the capacity to cross the blood brain barrier and manipulate extra- and intracellular functioning. For a disease with no cure and no treatment targeting disease progression,
simvastatin is a well-understood drug with great therapeutic potential.
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